Mangas C, Paradelo C, Rex J, Ferrándiz C
Servicio de Dermatología. Hospital Universitari Germans Trias i Pujol. Badalona. Barcelona. España.
Actas Dermosifiliogr. 2008 Jun;99(5):331-48.
Sentinel lymph node biopsy was introduced into the management of cancer patients 20 years ago. Most hospitals now currently use the technique as a routine diagnostic tool in patients with localized malignant melanoma. However, the technique is complex and numerous details need to be determined and assessed to provide reliable diagnostic and prognostic information. In addition, the introduction of immunohistochemical and molecular techniques in the last decade has extended the information provided by the study of sentinel lymph nodes and created valuable opportunities for investigating the pathogenesis of this type of cancer. The aim of this review is to offer the reader a detailed analysis of the most important studies in the literature and the factors that should currently be considered in determining the indication for sentinel lymph node biopsy, performing the procedure correctly, and interpreting the findings in patients with malignant melanoma.
前哨淋巴结活检于20年前被引入癌症患者的治疗中。现在大多数医院将该技术作为局限性恶性黑色素瘤患者的常规诊断工具。然而，该技术复杂，需要确定和评估众多细节以提供可靠的诊断和预后信息。此外，过去十年中免疫组织化学和分子技术的引入扩展了前哨淋巴结研究提供的信息，并为研究这类癌症的发病机制创造了宝贵机会。本综述的目的是为读者提供文献中最重要研究的详细分析，以及目前在确定前哨淋巴结活检的适应证、正确实施该操作以及解读恶性黑色素瘤患者的检查结果时应考虑的因素。
